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ABSTRACT 
 
 
 
 
BACKGROUND AND OBJECTIVES OF THE STUDY 
 
Myocardial  infarction  is  one  of  the  commonest  cause  of  death  in  the 
developing and developed countries. Indians are more prone to coronary artery 
disease but conventional risk factors do not explain the high rates of Coronary Artery 
Disease  among Indians. Myocardial infarction is claiming a large number of lives  
i n  i n d i a .  An  impressive difference was absence of traditional risk factors in a third 
of them. Novel risk factors like homocysteine, lipoprotein (a), small LDL particle and 
fibrinogen may play a significant role in these patients. The aim of this study is to 
estimate fibrinogen levels in  myocardial infarction patients and to study association 
of these novel risk factors with conventional risk factors. 
 
 
 
METHODOLOGY 
 
The present study included 70 patients who were admitted  to IM C U a nd  
IC C U of  T ha nja vu r  med i ca l  co l l eg e h ospital during the period of O c t  
2011–Nov 2012 fulfilling WHO criteria for acute myocardial infarction, presenting 
within 48 hours.  Traditional risk factors  were   studied  in  addition  to  studying    
plasma fibrinogen levels. 
 
 
 
RESULTS 
 
This  study  was  predominantly  male  oriented  49(80%).  Mean  age  of  the 
patients  was  52.26   years.  Chest  pain  was  the  most  common  presenting  
symptom present in all the   patients followed by sweating 10 (14.3%). 
Dyslipidemia  was the most 
 
 
 
common 42  (60.9 %) risk factor in the present study followed by smoking 39 (55.7 %). High  
mean plasma  fibrinogen  (440.61 ± 75.4 mg/dl) levels  was noted among patients. 
Significant association was noted between plasma f i b r i n o g e n    and  risk  factors   like  
dyslipidemia,  obesity , diabetes  and  smoking .  High plasma fibrinogen   was  observed  in 
patients with  chronic alcoholism, but not statistically significant. 
 
 
 
INTERPRETATION AND CONCLUSION 
 
In addition to the conventional risk factors of myocardial infarction, a high plasma  
fibrinogen levels were noted in patients with acute Myocardial infarction. 
However, larger studies need to be done to substantiate these findings. 
 
 
 
 
KEY WORDS: Myocardial infarction, Fibrinogen, Smoking, Dyslipidemia,   Obesity. 
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INTRODUCTION 
Cardiovascular disease is one among the major global health problems 
presenting in epidemic proportions. Myocardial infarction  is one of the 
commonest cause of death, including low and middle income countries.  India 
is in a transition phase from the state of high incidence of communicable 
disease to a state of high incidence of non communicable disease. India’s 
contribution to  the rising  global  burden  of coronary artery disease is  
significant.1   
High  risks  of coronary artery disease  reported  in  south  Asian 
populations,  particularly in  Indians  regardless of  the country in which they 
live. 
During the last twenty years it is noted that Indians have a higher 
incidence of coronary artery disease. Myocardial infarction claims a  large  
number  of  lives  even  before  they reach fifth decade of life. Myocardial 
infarction occurring at early age is associated with absence of usual risk 
factors such as systemic hypertension,  smoking,  diabetes  mellitus  and  
hyperlipidemia  in  about  one  third  of them.2 
The coronary artery disease  manifest as acute coronary syndrome  
including  unstable angina, ST elevation MI and Non ST elevation MI.  There 
is increase in mortality and complications associated with ST elevation MI. 
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Acute  myocardial infarction is due to sudden interruption of coronary 
blood flow. It is the complication of thrombotic occlusion of already narrowed 
coronary artery due to atherosclerosis. 
 
The mortality following the acute coronary event depends on the size of 
the infarct. The left anterior descending supplies wide areas including bundle 
branches, ventricular wall and septum hence its occlusion results in larger area 
of infarct.  
 
Salient features of coronary artery disease among Indians when compared 
to other ethnic groups.3 
  More than two fold higher prevalence 
  A decade earlier  onset of first MI 
  Nearly fivefold higher incidence of MI and mortality  in younger  
population less than 40 years 
  Severity of the disease 
  Lower prevalence of traditional  risk factors 
  Higher prevalence of newer risk factors including fibrinogen,  
homocysteine,  lipoprotein (a)  and  apolipoprotein B 3 
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AIM OF THE STUDY 
 
1.  To study fibrinogen levels in subjects with acute myocardial infarction. 
2.  To  compare  the  novel  risk  factors  like   fibrinogen  with conventional   
risk  factors  like  smoking, hypertension,  diabetes  mellitus,   obesity and 
dyslipidemia. 
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REVIEW OF LITERATURE 
Myocardial infarction 
Definition  
The World Health Organisation (WHO) definition includes the presence 
of two of the following4 
1.  Symptoms of myocardial infarction 
2.  Cardiac markers (enzymes) elevated  
3.   ECG showing characteristic electrocardiographic changes 
 
Newer diagnostic criteria according to the American College of 
Cardiology   and European   Society   of Cardiology.5   
It requires the presence of one of the following diagnostic criteria to 
satisfy the diagnosis of acute, evolving or recent myocardial infarction. 
1.  Typical rise and gradual fall (troponin I/T) or more rapid rise and fall 
(CK-MBs) of biochemical markers of cardiac muscle necrosis with any 
one of the following:  
          a.   Symptoms of myocardial ischemia 
          b.   Appearance of pathological Q waves in ECG 
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c. ECG changes suggestive of ischemia (ST segment elevation / 
depression) 
d. Coronary artery intervention (Eg. Coronary angioplasty) 
     2.  Pathological findings of an acute Myocardial infarction 
 
Risk factors 
According to American heart association (AHA) prevention conference  
held in 1999, risk factors  are classified  to three categories.6 
 
1.  Traditional /Conventional risk  factors.  
 Cigarette smoking,  
 Low HDL cholesterol  
 Elevated serum cholesterol  
 Hypertension 
 Diabetes mellitus 
2.  Predisposing factors 
 Male  sex 
 Physical inactivity 
 Family history of CAHD  
 Overweight & obesity 
 Insulin resistance 
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3.  Conditional factors  
 Homocysteine 
 Fibrinogen 
 Small LDL particle 
 C-reactive protein 
 Lipoprotein (a) 
 
 Emerging  risk factors                                
 Nitrotyrosine 
 Oxidative stress 
 Asymmetric dimethylarginine 
 Myeloperoxidase 
 
Smoking 
Cigarette smoking is the one of the most important modifiable risk 
factor. It interacts with other risk factors to increase the risk multi fold. It  
accelerates coronary atherosclerosis in men and women, at all ages. Smoking   
increases the risk of thrombosis, plaque rupture, myocardial infarction, 
arrythmias and sudden death. 
 
 
 
 8 
 It increases the oxygen demand of myocardial tissue and hence worsens 
angina.  Coronary artery disease  causes about   40%  of   smoking  related  
deaths,  and in addition to it around 8% of them  attributable to passive smoke 
exposure. 
 
The most  important  and modifiable cause of coronary heart disease 
and death is smoking. Smoking  correlates strongly   with   atherosclerotic   
disease ,    usually  in association  with other risk factors.7 
 
It  has been  found   that  28%  of  all  deaths  from  coronary  heart  
disease  are attributed to tobacco smoking. Compared with non-smokers, 
current smokers have a 70% increased risk of fatal coronary event  and a two 
to four fold increased  risk of non-fatal CAD.8 
 
In a recent major overview, smoking cessation reduced coronary heart 
disease mortality by 36%  as compared with mortality in subjects who 
continued smoking.9 
 
Smoking was the most common risk factor (87%) in a study by Siwach 
SB et al. who studied the profile of acute MI in young patients (below 40 
years).10 
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 Hyperlipidemia 
Abnormalities in plasma lipoproteins  and derangements in lipid 
metabolism rank as the most firmly established and best understood risk factor 
for atherosclerosis. The  4S   trial   demonstrated   an   approximately   40%   
reduction  in   incidence   of myocardial  infarction  as  well  as  a  further  
reduction  in  the  need  of  procedural intervention in hyperlipidemic 
individuals.11 
 
In a  study  by  Weinberger  et  al.,  hyperlipidemia  was  present  in  
only  four patients among 30 young patients.12 
 
In a study by Kanitz et al., Hyperlipidemia was present in 20% of young 
adult patients.13 
 
Hypertension 
The elevated blood pressure has been shown to be associated with  
accelerated  atherosclerosis  and  coronary heart disease. Elevated systolic 
blood pressure/diastolic blood pressure is clearly associated with an increased 
risk of coronary heart disease.14 
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In Framingham heart study even high normal blood pressure augements 
risk of cardiovascular disease two fold compared with lower levels. 
 
Hypertension is not a common risk factor in CAD in young adults. In a 
study by Zimmerman FH et al., hypertension and diabetes were more frequent 
in older men and women.15 
 
In study by Al Khadra et al., hypertension was documented in 18.5% of 
young individuals with acute myocardial infarction.16 
 
 Diabetes mellitus 
Diabetes mellitus  is  the most important   CAD  risk  equivalent.  Most 
diabetic patients die of atherosclerosis and its complications.  
The dyslipidemia present in diabetic patients is responsible for the  
elevated cardiovascular risk. The coronary artery disease is responsible for 
three fourths of all deaths in  diabetic patients.17 
There is  endothelial  and smooth muscle function impairment in 
diabetic patients. They also have increased adhesion of leukocytes to the 
vascular endothelial surface. This is very important step in atherosclerosis. 
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Patients with diabetes mellitus have two to eight fold higher rates of 
future cardiovascular  events  as  compared  with  age  and  ethnically  
matched  non-diabetic individuals. 
 
In a study by Barbash GI et al. few young patients with MI had history 
of hypertension and diabetes mellitus.18 
 
In a Nurse’s health study, women who eventually developed type 2 DM, 
the relative risk of MI was increased 3 fold before the diagnosis of diabetes.19 
 
In a  study  by  Al  khadra  30.8%  of  young  patients  with  MI  had  
diabetes mellitus.16 
 
Gender 
Men have increased risk of atherosclerosis than women. It is the most 
important  predisposing factor for coronary atherogenesis. The female sex  
have  protection from coronary atherogenesis. This effect is due to the 
estrogen. After menopause however, coronary risk accelerates  in   women.20 
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The Framingham study found a greater than two fold age adjusted 
increase in risk  for   CAD  among  post  menopausal  females  compared  with 
premenopausal females. Data  from the Framingham cohort also indicate that 
there are sex specific differences in the manifestations of CAD.21 
 
Male : Female ratio was 20:1, in study of profile of acute MI in young 
patients by Siwatch SB et al. 10 
 
Physical activity and Obesity 
Regular physical activity is associated with cardio protective effect. It 
increases exercise capacity. It also reduces the oxygen demand of cardiac 
muscles. Hence it  lowers the coronary risk. Cardioprotective  effects of 
exercise include adiposity,  diabetes incidence, lowered blood  pressure,  
improved  coronary  endothelial  function,  lower  CRP  levels,  and appears  
to  benefit  hemostatic   variables  including  tissue  plasminogen  activator, 
fibrinogen, VWF, fibrin D dimer and plasma viscosity. 26   
 
A consistent series of prospective studies have demonstrated an 
association between levels of physical activity and reduced rates of 
cardiovascular mortality and morbidity. 
 
 
 
 13 
In a prospective Harward study, those men with highest levels of 
activity at baseline had a 40% reduction in non-fatal cardiovascular events and 
24% reduction in cardiovascular mortality compared with those with sedentary 
lifestyle.22 
 
In  the  women  health  iniative,  walking  briskly  for  30  mins,  
5days/week associated with 30 % reduction in vascular events over a period of 
3.5 years follow up.23 
The  American  Heart  Association  has  recommended  an  exercise  
energy expenditure approaching  2000 calories each week,  a level of exercise 
that can be achieved with modest daily exertion.24 
 
Recent studies indicate that waist / hip ratio, a surrogate marker for 
centripetal obesity is associated with coronary risk.  This ratio  holds good as a 
independent factor  in both sex. 25 
 
Novel atherosclerotic risk factors 26 
Several   newer risk   markers   of   atherothrombotic   risk   are 
identified. They are proved by epidemiological studies. They are useful 
clinically. They are fibrinogen,  lipoprotein  (a),  plasminogen  activation  
inhibitor-1,  homocysteine and  high  sensitivity  C reactive protein. 
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C reactive protein 
CRP  is a acute phase reactant. CRP is a member of the pentraxin 
family. It plays  important   role  in  the  human  innate  response.  Apart from 
this effect , it directly affects vascular vulnerability. Levels  of CRP greater 
than  3 mg/L also appears to predict recurrent coronary events. 
 
Lipoprotein(a) 
                    It was first described in detail by Berg et al. Its clinical 
importance was described by Mclean et al.  They have structural similarity 
with apoprotien (a) and plasminogen. 
 
It has LDL  particle  with    apo  B-100. This   component  is linked  by  
a disulphide bridge to apoprotien (a). 
 
Apoprotien (a) is member of a family of ‘KRINGLE’ containing 
proteins. Other members of this family include proteins such as Plasminogen, 
Prothrombin, Factor XII, urokinase type Plasminogen activator and 
Macrophage stimulating factor.  
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Lipoprotein(a)   acts   by   binding on the endothelium.  It competes 
with plasminogen.  It binds to plasminogen receptor on endothelium.  Thus it 
reduces the activity of plasminogen. Many epidemiological studies proves  
positive  relation  between  lipoprotein(a)  and atherogenic risk. 
 
Their plasma concentration is  inversely proportional to the size of 
apoprotein isoform. Thus small isoforms are associated with higher plasma 
Lp(a) concentration.  
 
At birth Lp (a) levels are low and adult levels achieved in two years. 
Levels are high in asian and African population. Levels above 30 mg/dl are 
significant. 
 
Serum Lp(a) levels elevated in type 2 DM, renal failure, menopause , 
hypothyroidism and malignancy. Height, weight, BMI, diet, weight loss and 
physical activity do not affect the level of serum lipoprotein (a).  
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 HOMOCYSTEINE 
Homocysteine was first described by botz and du vizwand in 1932, 
however a link to human disease was not suggested until 1962. 
 
 
 
 
 
 
 
Structure of Homocysteine 
The person who first described pre mature atherosclerosis in children 
and young individuals is Dr. McCully .In  1960s  he demonstrated that  
atherosclerosis is present   in children with disorders  of homocysteine 
metabolism.   
 
Dr. McCully demonstrated that atherosclerosis  could  be due to high 
homocysteine levels. He postulated the same cause for atherosclerosis in 
adults also. He hypothesized that elevated  homocysteine  levels is the cause 
for   atherosclerosis,  but  this was not widely accepted. 27 
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Homocysteine is a Intermediate derivative in  the metabolism of  
methionine.  This amino acid contains thiol containing group. Less than 1% 
circulates as free form (reduced state).  Nearly 75%  is bound to  serum 
albumin. Around  25 % combines with  other thiol containing amino acids or 
with itself  to form dimer compounds. 28 
 
Homocysteine (reduced) 1% 
 
Protein bound homocysteine mixed disulphide (oxidised) 70-80% 
 
Homocysteine (oxidised) 5-10% 
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Homocysteine- cysteine mixed disulphide (oxidised) 5-10% 
 
Metabolism of homocysteine 
The  important 3 processes involved are as follows 28 
 Demethylation 
 Transmethylation 
 Transamination  
 
Demethylation 
In Demethylation  methionine  is converted to   homocysteine . 
In this process various  intermediate metabolites are formed including                  
S-adenosyl homocysteine  & S-adenosyl methionine . 
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Fig. 1 : Metabolism of Homocysteine 
This chart describes the metabolic pathways of Homocysteine in a 
nutshell. It describes both remethylation and transsulfuration pathways in our 
body. 
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Transmethylation 
In transmethylation pathway homocysteine is again converted to       
methionine.  Homocysteine  is  again remethylated to methionine in  liver , by  
enzyme  betaine-homocysteine  methyl  transferase. This step   is catalysed by 
methionine synthase . Vitamin B12  is used  as a co-factor.  Methyl 
tetrahydrofolate  acts as a substrate. 
 
Transsulfuration 
It is the process by which homocysteine is converted to cysteine. This 
reaction is irreversible process.  In  this  pathway    cystathionine  β synthase 
which is  vitamin  B6 dependent acts as catalyst.  By this process cystathionine 
is formed as intermediate.  Finally cystathionine is hydrolysed and it produces  
cysteine. 
 
Measurement and Classification of Homocysteine Levels 
 The normal plasma homocysteine  is 5-15 μmoles/L. Plasma 
homocysteine level greater  than 15 μmoles/L  is  considered  as 
hyperhomocysteinemia. 
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The American  Heart  Association  have  defined hyperhomocysteinemia  
as being divided into29 
Moderate  : 15-30 μmoles/L  
Intermediate : 30  - 100 μmoles/L 
 Severe  : >100 μmoles/L 
Various methods of estimation of plasma homocysteine 30 
1  High   liquid chromatography 
2  ELISA 
3  Mass spectrometry 
4  Fluorescence  polaraization  immunoassay 
 
Types of  hyperhomocysteinemia 
They are broadly divided into  2 types of  hyperhomocysteinemia.31 
1.  Primary & 
2.  Secondary 
1. Primary hyperhomocysteinemia 
Due to defect in  homocysteine  metabolism pathways like: 
a. Deficiency of Cystathionine beta synthase (CBS) : 
It is the  commonest cause of hyperhomocystinemia . It is transmitted as 
autosomal recessive trait.  It occurs in frequency of 1 per 3 lakh live births.  
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        The important clinical features are  skeletal deformities, premature 
atherosclerosis , mental  retardation and  dislocation of lens  . About   one 
percent  of  the  general  population  have   cystathionine beta synthase 
deficiency, in heterozygous state. They  have homocysteine levels elevated  in 
the range of 20-40 micromol/L. 
 
b. Deficiency of MTHFR (5,10 methylene tetrahydrofolate reductase ) 
The gene for enzyme MTHFR is mutated. It results in 
hyperhomocysteinemia associated with  low folic acid. 
 
c. Deficiency of Methylene tetrahydrofolate homocysteine methyl 
transferase 31 
2. Secondary hyperhomocysteinemia 
      a. Physiological 
 Elderly age group 
 Men  
 Post menopausal 
    b. Modifiable  factors   
 use of  Tobacco 
 consumption  of Coffee 
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  c. Vitamin deficiency   -  
 Folate  
 Vit B6 (pyridoxine), 
 Vit B12 (cobalamine) 
d. Systemic disorders 
 (i) Psoriasis   
(ii) Anorexia nervosa   
(iii) Systemic lupus erythematosus  
(iv) Pernicious anaemia 
(v) Hypothyroidism 
(vi) Renal failure    
(vii) Liver failure 
(viii)  Organ transplantation 
 
e. Drugs (toxins) 
1) Cholestyramine ,Colestipol ,Metformin (affect folate and cobalamin 
absorption) 
2) Folate antagonists  
- Phenytoin 
- Carbamazapine 
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3) Vit B6  antagonists (Theophylline, Oestrogen containing OCP ,Niacin) 
4) L-dopa (increases transmethylation) 
     5) Androgens 
    6) Cyclosporins ,Fibric acid derivatives (reduces renal function) 
    7) Nitrous oxide (inactivates methionine synthesis) 
Determinants of plasma total homocysteine32 
 Fasting plasma homocysteine 
Sex Male 10.3 
 Female 8.8 
Age (years)   
 < 45 8.8 
 45-54 9.2 
 54-64 9.8 
 > 65 10.4 
Serum creatinine (mol/L)   
 < 79 8.7 
 79-87 9.3 
 87-96 9.3 
 96-106 9.7 
 > 106 10.5 
Alcohol intake (g/d)   
 0.1-4.9 9.3 
 5-14.9 9.4 
 > 15 10.0 
Caffeine intake (mg/d)   
 < 88 8.9 
 > 420 9.9 
Current cigarette smoking  
 0 9.3 
 1-15 9.9 
 16-25 10.1 
 ≥ 26 11.0 
Body mass index (kg/m2)   
 < 23.2 9.4 
 ≥ 30.6 9.9 
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Dietary intake of folate in a  dose  of  0.5  to  5  mg reduces   
homocysteine levels by 24 %.  Vitamin B12 in addition   reduces to about 7%.  
Renal failure  raises plasma homocysteine due to reduced renal  
clearance . 
 
Coffee intake and smoking showed positive association with 
homocystiene. Moderate alcohol lowers while  chronic alcoholics 
have  increased plasma homocysteine. 
 
Effects of  Homocysteine on vascular endothelium 28 
It  produces damage to vascular endothelial surface & accelerates 
atherosclerosis. It is also associated with thrombo embolism.  It  affects   
smooth  muscle  cells, coagulation factors, connective tissues , plasma 
lipoproteins and  platelets. It also affects production of  nitric oxide. 
 
It   stimulates the proliferation of  vascular  smooth  muscule  .  It 
increases DNA synthesis and  cyclin A. It causes platelet aggregation and 
increases platelet adhesion. The inhibition of  Na+ - K+ - ATPase activity by 
Homocysteine is responsible for  hemolysis of Red blood cells. 
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Hyperhomocysteinemia  favours atherosclerosis 34 
Endotheial cell dysfunction is prerequisite for development of 
atherosclerosis. Homocysteine  is  toxic  to   endothelial  cell surface  by  
generating  oxygen  free  radicals. Sulfydryl  group reacts   to  ferric  or cupric  
ions and gets oxidized to synthesis hydrogen peroxide.  This reaction also 
produces oxygen free radicals  and homocysteine radicals. 
 
Homocysteine  gets auto-oxidized to form Homocysteine mixed 
sulphides and homocysteine thiosulphates.  There by it liberates hydrogen 
peroxide and  superoxide anion.  Hydrogen peroxide implicated in vascular 
injury of hyperhomocysteinemia. 
 
The oxidation of LDL by  Homocysteine causes vascular injury   .   
Homocysteine   thiolactone a byproduct oxidises  native  LDL. This step 
produces   oxidised  LDL  which  when taken  up  by  intimal macrophages of 
vascular endothelium   forms foam cells. This step initiates  the early stage of 
atheromatous  plaque formation. Homocysteine  reduces synthesis of   
endothelial  derived relaxing  factor  (NO).  NO  is a  potent  antiplatelet  
agent. It also  inhibits   production of hydrogen peroxide.  
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Hyperhomocysteinemia  may  interfere  with  antithrombotic  and  
fibrinolytic mechanisms  of  the  endothelium,   making   it  prothrombotic.   
Homocysteine causes  collagen deposition in  atheromatous plaques .  It also 
increases  of proliferation of vascular smooth muscle cells . 
 
Homocysteine decrease   the  activity  of antioxidant enzymes. This 
effect is responsible for proliferation of smooth muscles of vascular 
endothelium by increasing their mitotic activity. 
 
Complications of hyperhomocysteinemia31 
 Hypertension  
 Cerebrovascular  accidents  
 Ischemic heart disease  
 Peripheral vascular disease 
 Venous thromboembolism 
 
Stroke and peripheral vascular disease  
Their  concentration is elevated  in patients with CVA (stroke)  and 
peripheral vascular disease (PVD) .  
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As regards cerebrovascular disease, eleven clinical studies looked at  
causal relationship   between  homocysteine  levels  and  cerebrovascular  
disease.  In  nine studies,  they have  significant  relationship  while  two  
prospective  studies  lacked evidence for an association. 
 
Hyperhomocysteinemia and venous thrombosis 
Hyperhomocysteinemia   can be considered as a factor which favours  
venous thromboembolism. 
Martin Den Haijer et al.36 studied the plasma homocysteine 
concentration of patients with  venous thrombosis. It was found to be  
elevated.  The  combination of  hyperhomocysteinemia  and  factor V further  
increases the  likelihood of  venous thromboembolism . 
 
Homocysteine and diabetes mellitus 
Type 2 diabetes mellitus patients who had macrovascular disease had 
elevated homocysteine  levels.   It was shown  that  hyperhomocysteinemia 
appears  to  be  a greater risk factor for cardiovascular  disease in them,  than 
the subjects  with normal/impaired glucose tolerance.37 
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Homocysteine and hypertension 
Bortolotto LA et al, demonstrated that hypertensive patients with 
elevated levels  of homocysteine  associates positively with arterial stiffness.38 
 
Homocysteine and renal disease 
Kidneys play an important role in homocysteine metabolism. Patients 
with renal failure have delayed clearance of homocysteine.  This  effect 
increases risk of atherosclerosis. 
 
Homocysteine and ischaemic heart  disease 
As regards CAD,  17  studies were evaluated, out of which  in  14 
studies, homocysteine was found to be a significant risk factor.  The CAD risk 
was around ten percent attributed to be  due to elevated homocysteine. It  was  
studied that reduction of  homocysteine levels   by  3  μmol/L  results in 30% 
reduction of  risk of  ischaemic heart disease.39 
 
Study done by Boushey et al.  shows that  increase in  homocysteine 
levels is associated with an increased risk of peripheral arterial disease, 
ischaemic heart  disease, CVA  and  venous thromboembolism.40 
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Studies by Arnesan et al illustrate  that  Homocysteine levels in study 
population  was  elevated than that of age and sex matched  controls. This 
shows that ,it is  an independent risk factor 41 
 
Nygard et al studied  587 angiographically documented cases.  He 
showed that  there is positive relation between  between their  elevated  levels 
and mortality. 42 
 
In Asian Indians, Chacko did his studies with CAD and plasma 
homocysteine. He stated that plasma homocysteine could not be statistically 
proven in Asian populations. 43 
 
Chambers et al. studied UK Indian Asians with CAD and compared 
them with Europeans having CAD. They studied 764 male patients (257 
Indian Asian and 507 European). Their  results  revealed  that  plasma  
homocysteine  concentrations  were higher in Indian Asians compared with 
Europeans. 44 
 
Ford et al, analyzed the prospective trails and concluded that there was  
20% increase in cardiovascular risk for every 5 μmol/L increase in 
homocysteine levels.45 
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Enas  A  Enas   et al found that women with homocysteine levels 
elevated above 16 μmol/L  have double  the  risk of  acute coronary event .46 
 
Stampher et al,  studied about coronary atherogenesis in doctors. His 
results are such that a rise in homocysteine concentrations ten to twelve 
percent is positively associated with three times the risk of acute coronary 
event. 47 
 
Homocysteine and aute coronary event  in young adults 
Myocardial infarction is claiming a large number of lives in young 
patients. Various studies have shown that homocysteine may be significant 
marker of risk in young patients lacking conventional risk factors . 
 
In  a  study  by  ogawa  et  al,   he discussed the role of homocysteine in 
myocardial infarction   (young adults)      and    concluded   that  increased 
concentration of plasma   homocysteine  is absolutely  a risk marker for 
myocardial infarction. 48 
 
Dr. Khare A.   studied the role of  homocysteine in patients with  acute 
myocardial infarction less than 40 years age. He  concluded that elevated 
homocysteine levels were independently associated with CAD. 49 
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VK Katyal et al., studied 100 young patients(less than 40 years) 
admitted with acute  MI  and found hyperhomocysteinemia to be a significant 
contributor towards premature CAD.50 
 
Study conducted by Puri A et al.  showed that  CAD is associated with 
homocysteine. He postulated that it can be taken as  a important  risk factor 
among  young CAD patients.51 
 
Stephen M Schwartz et al studied 79 women of age < 45 years 
diagnosed with MI and concluded that elevated plasma homocysteine and low 
plasma folate are risk factors for MI among young women.52 
 
TREATMENT 
The      effective     way   of   reducing  homocysteine  concentration in 
plasma is to  treat with folates, vitamin B6  and  B12. A strong negative  
correlation between folic acid levels and their   homocysteine levels has been 
proven. 
 
 
 
 
 
 33 
   Guidelines  of  the  American  heart  association  advocate  the  
principle  of screen  and treat, i.e., screening for hyperhomocysteinemia is 
recommended only in high  risk  population  (personal  or  family  history  of  
premature  atherosclerosis, myocardial infarction, hypertension, diabetes). 
 
It is recommended to keep the homocysteine levels to <10μmol/L in the 
high risk   group.  Those  with  hyperhomocysteinemia  should  be  treated  
with  dietary modification  followed  by  vitamin  supplementation  or  
fortification  of  food  with vitamins (400 μgm of folic acid, 2mg of vitamin 
B6 and 6μgm of vitamin B12). 53 
 
In the  vitamin intervention for prevention of  stroke trial,  the benefit of  
high dose vitamin therapy over vascular events  was not established.  The  
effect on stroke, CHD events, and  death could not be proved. 54 
 
Results have  shown  that  folic  acid  supplementation reduced 
plasma homocysteine by 41%, whereas Vit B12  supplement lowered 
homocysteine level by 14.8% and both were significant.  But vit B6 therapy 
did not reduce homocysteine levels. 
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The  combination  of  three  vitamins  reduced  plasma homocysteine by 
49.8%.  55 
 
FIBRINOGEN 
It  is a part of coagulation cascade. It regulates blood flow and viscosity.  
Now  studies shows that  elevated plasma concentration of fibrinogen is  
associated with vascular events like  CVA , thrombo embolic phenomenon and 
coronary artery disease.  
Nevertheless,  the   role of fibrinogen in causing,  atherosclerosis is 
complicated. The atheroma formation is similar in process to thrombogenesis. 
This step involves  various other thrombogenic factors also.  The major 
contributor is fibrinogen. Thus it has detrimental effects on vascular 
endothelium.  
 
Fig. 2 : Schematic model of fibrinogen 56 
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STRUCTURE OF FIBRINOGEN MOLECULE 
The fibrinogen is a  glycoprotein.  Molecular  weight around  340 kDa. 
Normal plasma concentration is 200 to 400n mg / dL.  It is a precursor to 
fibrin. Length is  45 nm .  Diameter  9 nm.  It consists  of three pairs of  
polypeptide chains . They are  namely alpha, beta & gamma chains.  They are 
held together  by  disulphide bonds. 
 
The  central  nodule  or  E-domain  is  5  nm  in  diameter  and  contains  
the NH2-terminal of all six polypeptide chains forming the NH2-terminal 
disulfide knot. The two outer D-domain nodules are composed of the                    
C-terminal two thirds of both the  Bβ  and  γ  chains.  Between  the  E-  and  
D-domains,  there  is  a  stretch  of approximately 120 amino acids from each 
of the three chains that forms an α-helical structure known as the coiled-coil 
domain. This region of the molecule is supported on both sides by a set of 
disulfide bonds called disulfide rings. These rings play an important  role  in  
making  fibrin  mechanically  strong  and  resistant  to  proteolysis. Structural  
elements  in  each  of  the  individual  chains  are needed for blood 
coagulation. 
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The Aα chain is a 610-amino acid polypeptide that can be divided into 
three distinct domains. The first section of the Aα chain (residues 1-194) 
contains a region (residues 45-161) linked to the Bβ and γ chains by disulfide 
bonds. This section forms part   of   the   α-helix   or   coiled   coil   domain.   
This   first   section   also   contains fibrinopeptide A (residues 1-16) and the 
polymerization site in the E domain. 
 
The Bβ  chain is  a polypeptide composed of  461  amino acids  and  is 
also divided  into  three  sections.  The  first  80  residues  contain  the  
fibrinopeptide  sequence  (residues  1-15)  and  a  site  that  supports  
endothelial  cell  spreading  and proliferation (residues 15-42). The middle 
section (residues 81-192) is linked to the Aα and γ chains through disulfide 
rings and forms part of the coiled-coil domain. 
 
The γ chain is only 411 amino acids long and is also divided into three 
distinct sections. Unlike the Aα and Bβ chains, there is no fibrinopeptide at the 
NH2-terminus of they chain. 
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The first 18 amino acids of the γ chain form part of the NH2-terminal 
disulfide knot,  the  middle segment of this polypeptide consists of amino 
acids 19-135. This section contains the disulfide rings that link this region to 
the Aα and Bβ chains in the coiled-coil domain. 
 
There  are  2  distinct  forms  of  γ  chains  in  human  plasma  
fibrinogen. Approximately  15%  of  the  γ  chain  contains  an  extended  C-
terminal  and  are designated γ’ chains. Although Fibrin polymerization and 
cross linking of γ’ proceed normally, the γ’ chain does not support platelet 
aggregation. The clinical significance of the γ’ chain remains unknown, 
however, recent studies suggest that γ’ is a carrier for the zymogen of factor 
XIII in circulating blood. 
 
Synthesis 57 
Plasma fibrinogen is synthesized in the liver by the hepatocytes.  It is 
released into circulation with  half life of  nearly 100 hrs. it is degraded at rate 
of 24 % per day. The turnover rate of fibrinogen is about 1.7 to 5.0 gm/day. 
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Function56, 57          
It is the clotting factor I, according to the system for naming blood 
clotting factors. It plays vital role in coagulation pathway. It produces fibrin on 
activation.   
 
Results in fibrin which binds to lipoprotein and LDL and retains lipid 
moiety in the plaque. It is also important mediator in inflammation and 
atherogenesis. It plays pivotal role in thrombogenesis. The possible 
mechanisms include increased blood viscosity and enhanced platelet 
aggregation. It also causes atherothrombosis by infiltrating the vessel wall. 
Thus they favour thrombus formation.  
 
Role in Inflammation 
They interact with WBCs by ‘integrins’.The integrins are surface 
receptors coated on the leukocytes.Mac1 and alpha X and beta 2 are the 
fibrinogen binding receptors.Mac1 is very specific for fibrinogen.  
 
Fibrinogen also bind with intercellular adhesion molecule-1 (ICAM-1) . 
ICAM-1 is otherwise called CD54.It is present over vascular endothelium.  
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Fibrinogen attaches with Mac1 and also interacts with ICAM-1 to cause 
adhesion of monocytes over vascular endothelium. Fibrinogen also 
upregulates the expression of ICAM-1 or CD54 over the vascular 
endothelium.  
Fibrinogen favours chemotaxis. Thus it is important in inflammation. 
This effect is mediated by binding with integrins receptors of leukocytes. As a 
consequence of this activation,the neutrophil activation markers are expressed. 
There is also increase in calcium concentration intracellularly.  
Fibrinogen favours cell to cell adhesion and also facilitate cell to 
collagen (extracellular matrix). Thus it facilitates the inflammatory response.  
 
Role in Thrombogenesis58 
There is a normal balance between coagulation and fibrinolytic 
pathways.Thrombosis initiated when the balance fails. 
Activation of Factor X to Factor Xa is the final step in coagulation 
pathway. This in turn converts prothrombin to thrombin. Thrombin facilitates 
conversion of fibrinogen to fibrin monomers. They adhere to each other to 
form fibrin clot. 
Fibrinogen plays definite role in platelet aggregation . they interact with 
glycoprotein IIb-IIIa receptor present on platelets to facilitate its aggregation. 
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Role in Atherogenesis58 
Fibrinogen plays pivotal role in causing endothelial damage. The fibrin 
formed upon activation of fibrinogen , initially acts over the intimal layer of 
the vessel wall and it promotes cellular proliferation.  
 
They favour cell migration and  cell adhesion. The fibrin degradation 
products are the main stimuli for chemotaxis, extracellular matrix synthesis 
and their proliferation. This affects the vascular permeability and their tone.  
There is clear evidence for large amount of fibrin deposition in the 
atherosclerotic lesions in the human blood vessels. They are present either 
over the intact surface of plaque or buried within the fibrous cap.  
 
Estimating fibrinogen levels 58 
  It is done by two  methods . 
1. Functional methods 
The Functional methods involves determining coagulation time. This is 
directly related to plasma fibrinogen concentration.Clauss method is widely 
accepted method. This is based on the time necessary for coagulation end 
point.  
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2. Direct method 
         This method  quantifies  the plasma concentration  directly. They are 
based on immunological or gravimetric methods. The disadvantage is that they 
do not give information about quality of there function. 
The normal plasma concentration varies circulating  from 200 – 400 
mg/dl. The widely accepted method is Clauss method.  
 
Determinants of  fibrinogen59 
1. Genetics: There is genetic polymorphism which accounts for 30 to 50 
percent variation.   
 
2. Gender :  According to Monica ausburgs,women generally have their 
fibrinogen levels elevated when compared with age matched men. This is 
irrespective of pregnancy. It is also independent of use of oral contraceptive 
pills. 
 
3. Smoking :  There is clear evidence for elevation of  fibrinogen associated 
with smoking. There is proportional increase of 350mg/dl with each cigarette 
smoked. Smoking causes inflammation of pulmonary alveoli and bronchus. 
This inturn increases concentration of IL-6 which promotes synthesis of acute 
phase reactants from liver. 
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4. Alcohol  : Mild to moderate alcohol intake reduces plasma  fibrinogen 
levels. According to DESIR study, those who do not take alcohol or heavy 
drinkers taking more than 70gms/day have more plasma fibrinogen values.. 
 
5.Obesity : They have positive relationship with body mass index, waist hip 
ratio and waist circumference in both men and women.  
 
6. Exercise : Regular physical activity reduces the level of fibrinogen. This 
effect attributes to the cardiovascular benefits of regular physical exercise.  
 
7. Hormonal Influence :  The use of oral contraceptive pills is associated 
with elevated fibrinogen levels 
 
8. Age  :   Fibrinogen has a tendency to increase with age. This is attributed to 
the delayed clearance from plasma.  
 
9. Role of Vitamins :    Dietary intake of Vitamin C reduces   plasma   
fibrinogen to a great extent.  
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10. Role of Infections:  Certain organisms like Helicobacter pylori and 
Chlamydia were implicated in causing coronary artery disease.The role of 
fibrinogen may be explained following these infections. Its level is also 
increased in periodontal infections. 
 
Factors  increasing fibrinogen  
 Old age, women  
 African and asian race 
 Over weight and obesity 
 Smoking  
 Post menopausal women 
 Combined oral contraceptives 
 Heavy alcohol drinkers 
 Sedentary life style 
 
Factors reducing fibrinogen 
 younger age group 
 Caucasians 
 Japanese race 
 Smoking cessation  
 Low to moderate alcohol intake  
 Regular physical activity 
 Weight reduction 
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Role  of Fibrinogen in acute coronary event 
Many statistical analysis and prospective studies clearly shows that 
elevated plasma fibrinogen is associated with acute coronary event. This 
suggests  the possibility of fibrinogen may be considered as a individual risk 
factor.59 
 
In one meta analysis, which included a large number of prospective, 
cross sectional and case control studies concluded that the risk is about two 
times with elevated fibrinogen levels. Thus higher plasma levels are associated 
with increased risk of acute coronary event.60 
 
In  Framingham  study,  the cardiovascular  risk  is directly related to 
their plasma fibrinogen levels. The risk of acute vascular event increases with 
levels above 4.5gm/dl 61 
 
In European  concerted  action  on  thrombosis  and  disabilities  study, 
they concluded that plasma fibrinogen can be taken as an independent risk 
factor. They provided it for acute coronary event as well as for sudden death. 
They also included measurement of plasma VWF and t-PA, in their studies.  
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The relationship with acute coronary syndrome is much stronger. This is 
proved statistically when compared with LDL cholesterol.62 
 
Deepa et al, studied prothrombogenic risk factors in south Indian with 
CAD and found that prothrombogenic risk factors particularly fibrinogen may 
be associated with CAD.63 
 
Fibrinogen and young MI 
Khare A et al. studied fibrinogen  levels in 120 patients with MI less 
than 40 years of age and concluded that fibrinogen is an independent risk 
factor.49 
 
Von Eyben et al. studied fibrinogen levels in 22 patients with MI aged 
less than 41 years, came to conclusion that fibrinogen was independent risk 
factors.64 
 
Elikowski W et al, studied thrombotic risk factor in 40 young survivors 
[aged 30-40 yrs] of myocardial infarction and found high fibrinogen levels 
among them.65 
 
 
 
 46 
Lewandowski k et al, studied 99 male patients aged less than 40 yrs 
with MI and found that the frequency of BcII polymorphism of the beta-
fibrinogen gene was significantly   higher  in  MI  patients  along  with  higher  
plasma  concentration  of fibrinogen.66 
 
Interventions to reduce its level  
Several drugs lower plasma fibrinogen concentrations, including some 
beta adrenergic blocking agents, platelet inhibitors, and fibric acid derivatives, 
but lifestyle modifications such as exercise and modest alcohol intake may be 
the most satisfactory initial treatment of choice.67 
 
Intervention to decrease plasma fibrinogen 59 
The most successful in reducing plasma fibrinogen levels includes drugs 
like fibrates, plasmapheresis, alcohol intake and most importantly by stopping 
smoking.  
 
         The other steps which yield doubtful benefits include hormone 
replacement in post menopausal women, weight reduction, lowering 
hypertension etc., Statins are not useful.  
         According to  Bezafibrate Coronary Atherosclerosis Intervention  Trial 
(BECAIT),  the benefit of therapy is mediated by fall in fibrinogen levels.68 
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MATERIALS AND METHODS  
SOURCE OF DATA 
Cases  for  the  present  study  were  selected  from  the  inpatients  of  
ICCU ward, IMCU ward in Thanjavur medical college Hospital,  Thanjavur  
between  Oct 2011  to Nov 2012.  
 
METHOD OF COLLECTION OF DATA 
Sample size: 70 cases 
Present  study  involved 70 patient  admitted to Thanjavur medical 
college Hospital  with  diagnosis  of  acute  myocardial  infarction.  A detailed  
history  and thorough clinical  examination was done as per the proforma and 
were investigated further. 
 
Inclusion Criteria 
1. Patients fulfilling WHO criteria for acute myocardial infarction . 
2. At least two of the three elements presenting within 48 hours 
     a.  History of ischemic chest discomfort 
             b. Typical  ECG changes 
             c. Elevated cardiac enzymes 
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Exclusion Criteria 
     1.  Patients with renal dysfunction/ Liver disease 
    2.  Patients with thyroid disease. 
 
The following parameters were studied 
Smoking :  Proper history of smoking obtained in  terms of pack years  &  
smoking index 
 
Diabetes mellitus 
1. Known  diabetics  and their duration of disease. 
2. Newly detected DM satisfying WHO criteria 
     a.   Symptoms of diabetes mellitus with random blood glucose >200 mg% 
    b.  Fasting plasma glucose > 126 mg%, 
    c.   2 hr plasma glucose  > 200 mg% 
 
Hypertension 
1. Known hypertensives on treatment and their duration of disease 
2.  Newly detected hypertension according to JNC VII criteria 
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Family history  of  Ischemic heart disease 
Obesity : Patients were classified accordingly as  overweight and obese based 
on body mass index. BMI = Weight (kg)/height (mt2) 
           Obesity  - BMI  > 30  
    Over weight -   BMI    25  to 30 
 
Dyslipidemia 
According  to  NCEP-ATP  III  guidelines,  patients  were  considered  
to  have dyslipidemia when 
1.  Total cholesterol  > 200 mg%, 
2.  HDL  < 40 mg%, 
3.  LDL  > 100 mg% 
4.  Triglycerides  > 150 mg%. 
 
Plasma fibrinogen level :  The levels were measured quantitatively by 
Coagulation method  done by SYSMEX 500 series. Serum   fibrinogen  values 
greater than 400 mg/dl is considered as hyperfibrinogenemia. 
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Other investigations 
ECG 
RBS,  
Blood urea 
Serum creatinine 
Cardiac enzymes –  CKMB 
 
Method of Statistical Analysis 
The data were  analysed  by  calculating  percentages,  mean values, 
standard deviation and standard error using one-sample T test, independent 
samples, chi-square T test and ANOVA – one way test. 
All  statistical  calculations  were  performed  using  the  software  SPSS  
for windows 14 evaluation version. 
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RESULTS 
 
In this study 70 patients with evidence of acute myocardial infarction 
were evaluated.  Novel risk factor fibrinogen studied in comparison with other 
conventional risk factors. 
 
Table – 1 : Age  wise Distribution of the cases 
Sl.no Particulars No.of respondents (n=70) 
Percentage 
(100%) 
1 30 to 40yrs 10 14.3 
2 41 to 50yrs 22 31.4 
3 51 to 60yrs 23 32.9 
4 61 & above 15 21.4 
 
In this study most of the cases were between the age group  of 51  to 60 
years. Youngest patient in this study was 30 year old. 
           Mean age among the cases was  52.26 years 
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Chart 1 : Age wise distribution of the cases 
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This graph  shows   age wise distribution of cases . Most of cases 
were in the age group 51 to 60 in our study. 
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Table – 2 : Sex wise Distribution of the cases 
 
Sl.no Particulars No.of respondents (n=70) 
Percentage 
(100%) 
1 Male 56 80.0 
2 Female 14 20.0 
 
This was a male dominated study with males comprising 80% of the 
study group. 
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Chart 2 : Sex wise Distribution of the cases 
Male Female
 
 This pie chart illustrates the sex wise distribution of cases. In our study   
males contribute to around 80% of cases.  
Table - 3 :  Difference between gender of the respondents and their 
P.fibrinogen 
T Test 
Sl.no P.fibrinogen (mg%) Mean  S.D Statistical inference  
1 Male (n=56) 439.54 72.104 
2 Female (n=14) 444.93 90.308 
T=-.238 
.813>0.05 Not 
Significant  
Df=68 
Statistical test: Student ‘t’ test was used the above table 
 In our study the mean plasma fibrinogen of females is higher than 
males .  But this is not statistically significant.  
 
 
 55 
 
 
Table – 4 : Symptoms at the time of admission 
 
Symptoms Number of cases  Percentage 
Chest Pain 70 100 
Sweating 10 14.3 
Vomiting / Nausea 5 7.1 
Breathlessness 7 10 
Palpitation 5 7.1 
 
Chest pain was the most common symptom which was present in all 
patients (100%) followed by sweating (14.3%) 
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Chart  3 : Symptoms at the time of admission 
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This bar  diagram shows symptom wise distribution of cases. In our study 
most common  symptom is chest pain.   
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Table –5 : Comparison of  risk factors among patients 
 
Risk Factors Number of Cases Percentage 
Dyslipidemia 42 60.9 
Smoking 39 55.7 
Diabetes Mellitus 24 34.3 
Hypertension 24 34.3 
Obesity 5 7.1 
F H – C A D 5 7.1 
 
 
In this study dyslipidemia  (60.9%) was the most common risk factor 
followed by smoking (55.7%). Diabetes  mellitus  and  hypertension  were  
observed  in  24 number of patients. Overweight was present among 50 % of 
patients and only 5 (7.1%) patient was obese. 34.3% of the study group were 
alcoholics. 
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Chart 4 : Comparison of risk factors among patients 
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This bar chart shows the risk factor  wise distribution of cases. In our study 
dyslipidemia is the most common risk factor ( 60 .9 %) , followed by  
smoking  (55.7 %).  
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Table –6 : Percentage of cases with hyperfibrinogenemia  
Risk factors Number of Cases Percentage 
Fibrinogen 47 67.1 
 
In this study significant number of patients (67.1%) had hyperfibrinogenemia. 
 
Chart  5 : Percentage of cases with hyper fibrinogenemia   
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Table –7 : Study of plasma fibrinogen levels in our patients 
 T-Test 
Study of  level of P.fibrinogen of the respondents  
Sl.no P.fibrinogen (mg%) Mean  S.D Statistical inference  
1 <400 (n=23) 352.78 41.974 
2 >400 (n=47) 483.60 44.054 
T=-11.847 
.000<0.05 Significant  
Df=68  
Statistical test: Student ‘t’ test was used the above table 
 
Risk factors Mean Values P value 
Fibrinogen (Normal 180-400 mg/dl) 440.61± 75.4 mg/dl 0.000<0.05 
 
        In  this  study  mean  plasma   fibrinogen level  was  (440.61± 75.4 
mg/dl), which  was high compared to the normal  fibrinogen levels and was 
statistically significant.  
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Chart  6:  Mean plasma fibrinogen in our study 
0
50
100
150
200
250
300
350
400
450
Fibrinogen
Fibrinogen
 
 
This chart shows mean plasma fibrinogen in our study (440.61 mg/dl) 
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Table – 8 : Comparison of mean plasma fibrinogen levels among smokers 
and non-smokers 
 
 Smokers Non – smokers P value 
Fibrinogen (mg/dl) 433.64± 72.08 421.3± 71.02 0.035<0.05 
 
          Mean fibrinogen   level (433.64mg/dl) was high among smokers when 
compared to non-smokers (421.3mg/dl), and was statistically significant  
 
Chart 7 : Comparison of mean plasma fibrinogen level among smokers 
and non smokers. 
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Table – 9 : Comparison of mean plasma fibrinogen levels among 
diabetics and non diabetics 
 
 Diabetics Non – Diabetics P value 
Fibrinogen (mg/dL) 463.33 ± 77.31 428.76± 72.4 0.046<0.05 
 
         Diabetics had higher values of fibrinogen (463 mg%)  when compared 
to non-diabetics (428 mg%) , which was statistically significant. ( p value 
0.046  < 0.05 ) . 
 
Chart  8 : Comparison of mean plasma  fibrinogen  levels among 
diabetics and non diabetics 
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 Table-10 : Comparison of mean plasma fibrinogen among hypertensives 
and non hypertensives 
 
 
Sl.no 
P.fibrinogen (mg%) 
Mean  S.D Statistical inference  
1 Hypertensive (n=24) 452.13 78.751 
2 Non hypertensive 
(n=46) 
434.61 73.759 
T=.922 
.360>0.05 Not 
Significant  
Df=68  
Statistical test: Student ‘t’ test was used the above table  
 
The mean plasma fibrinogen in hypertensives  ( 452.13 mg/dl ) was  high  
when compared with non hypertensives ( 434.61 mg/dl ), but this difference is 
not statistically significant.   
Chart 9: Mean plasma fibrinogen among hypertensives and non 
hypertensives  
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Table 11: Comparison of mean plasma fibrinogen of alcoholics and non 
alcoholics   
Oneway ANOVA difference between alcohol of the respondents and their 
P.fibrinogen 
Sl.no P.fibrinogen 
(mg%) 
Mean S.D SS D
f 
MS Statistical 
inference 
1 Between 
Groups 
  11616.973 2 5808.486 
2 Nil (n=46) 446.85 75.4
19 
   
3 CR (n=13) 443.69 56.6
96 
   
4 OCC (n=11) 410.91 92.8
15 
   
5 Within 
Groups 
  380677.613 6
7 
5681.755 
F=1.022 
.365>0.05 
Not 
Significant 
Statistical test: Oneway ANOVA ‘f’ test was used the above table 
 
The mean plasma fibrinogen of chronic alcoholics is higher than occasional 
alcoholics , but it is not statistically significant.  
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Table – 12 : Comparison of mean plasma fibrinogen levels among 
patients with high   LDL level and patients with normal  LDL  
 
Sl.no Particulars (LDL mg %) 
No.of 
respondents 
(n=70) 
Percentage 
(100%) 
1 Below 100 28 40.0 
2 100 to 129 26 37.1 
3 130 to 159 11 15.7 
4 160 & above 5 7.1 
 
Sl.no 
P.fibrinogen 
(mg%) 
Mean S.D SS Df MS 
Statistical 
inference 
1 Between Groups   7622.973 3 2540.991 
2 Below 100 (n=28) 428.86 79.774    
3 100 to 129 (n=26) 449.15 73.408    
4 130 to 159 (n=11) 453.00 69.146    
5 160 & above (n=5) 454.80 67.059    
6 Within Groups   384671.613 66 5828.358 
F=4.436 
.031<0.05 
Significant 
 
          Subjects with high  LDL ( > 100 mg %) had their Plasma fibrinogen   
Concentration ( 445. 65 mg % )  higher than  persons with  normal LDL  
(428.86 mg %) 
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Chart 10 : Comparison of mean plasma  fibrinogen levels among patients 
with dyslipidemia and patients with normal lipids 
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460
below 100 100 to 129 130 to 159 160 and above
below 100 100 to 129 130 to 159 160 and above
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 Table 13 :  Comparison of HDL level and mean  plasma fibrinogen    
T-Test 
Difference between level of HDL of the respondents and their 
P.fibrinogen 
Sl.no P.fibrinogen (mg%) Mean  S.D Statistical inference  
1 Less than 40 (n=15) 456.20 82.755 
2 More than 40 (n=55) 436.36 73.507 
T=.902 
.601>0.05 Not 
Significant  
Df=68 
Statistical test: Student ‘t’ test was used the above table  
 
In our study  subjects  with HDL level above 40 mg/dl ,their  plasma 
fibrinogen level is lower .  But this difference is not statistically significant.  
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Table – 14 : Comparison of mean fibrinogen levels among patients with 
obesity  and patients with normal BMI 
 
Sl.no Particulars 
No.of respondents 
(n=70) 
Percentage 
(100%) 
1 20 to 25 30 42.9 
2 25 to 30 35 50.0 
3 30 & above 5 7.1 
 
Sl.no P.fibrinogen (mg%) Mean S.D SS Df MS 
Statistical 
inference 
1 Between Groups   29428.819 2 14714.410 
2 20 to 25 (n=30) 438.23 73.520    
3 25 to 30 (n=35) 432.20 77.393    
4 30 & above (n=5) 513.80 24.823    
5 Within Groups   362865.767 67 5415.907 
F=4.717 
.043<0.05 
Significant 
 
     The  mean plasma fibrinogen in  BMI  < 25   is  438.23 mg/ dl .    The 
mean plasma fibrinogen in BMI between 25  to 30  is 432.20 mg /dl.  In obese 
group plasma fibrinogen is around 513.80 mg/dl. The difference is 
statistically significant. 
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Chart  11 : Comparison of mean  fibrinogen levels among patients with 
obesity and over weight and patients with normal BMI 
 
 
380
400
420
440
460
480
500
520
20 to 25 25 to 30 30 & above
Fibrinogen
 
This chart describes the correlation between BMI and the plasma 
fibrinogen of the study group which is statistically significant. 
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DISCUSSION 
 70 patients of with  evidence  of  acute  MI admitted to ICCU and 
IMCU  were studied  and  the following data were compared. 
 
Table - 15 : Comparison of sex wise distribution of the cases  
Study Males % Females % 
SK mishra et al69 90 10 
Khare A et al49 91.67 8.33 
AL Khadra et al16 96.9 3.1 
Ranjit N72 86 14 
Present  Study 80 20 
 
Sl.no Particulars 
No.of 
respondents 
(n=70) 
Percentage 
(100%) 
1 Male 56 80.0 
2 Female 14 20.0 
 
The study was predominantly male (80%) dominated. This may be 
attributed to the protective effects of estrogen in pre-menopausal women. This 
was comparable to the other studies. 
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Table - 16 : Comparison of age wise distribution of the cases 
 
Sl.no Particulars No.of respondents (n=70) 
Percentage 
(100%) 
1 30 to 40yrs 10 14.3 
2 41 to 50yrs 22 31.4 
3 51 to 60yrs 23 32.9 
4 61 & above 15 21.4 
  
In our study, mean age of the patients was 52.26 years. 
 
Most of the patients were in the age group between51 to 60 years (32.9%). 
Study Age (Mean) in years 
Present Study 52.26 
Romero M  et al50 56.4 
Hampten  et al71 57.03 
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Table – 17 : Comparison of symptoms at admission  
 
Symptoms Mishra SK et al.69 Patil CN et al.71 Present Study 
Chest Pain 83.4% 93.3% 100% 
Sweating 61% 50% 14.3% 
Vomiting / Nausea 5% 16.7% 7.1% 
Breathlessness 29% 16.7% 10% 
Palpitation - 3.3% 7.1% 
Stroke 0.8% - - 
Syncope 6% - - 
 
 
In our  study chest pain (100%)  was the most common symptom 
followed by  sweating (14.3%). Similar findings were noted in study by 
Mishra et al and Patil et al .  
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Table - 18 : Comparison of risk factors 
  
 
Risk Factors 
Al. Khadra et al16 Puri  et al70 Mishra SK et al69 Present 
Study 
Dyslipidemia 33.8% 58.8% 52% 60.9% 
Smoking 76.9% 52% 75% 55.7% 
Diabetes 30.8% 21.5% 16.5% 34.3% 
Hypertension 18.8% 54.9% 23% 34.3% 
Obesity 15.4% 23.3% 37% 7.1% 
F H – C A D - - 33.8% 7.1% 
  
Dyslipidemia  (60.9%)  was  the    most  common  risk  factor  which  
was comparable with other studies, Al. Khadra et al (33.8%), Mishra et al 
(52%).  
In our study  smoking is present in 55.7 %  and  7.1 % patients  are 
obese. Other risk factors like hypertension, Diabetes mellitus and family 
history of CAD were present in a few patients. 
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Table - 19 : Comparison of mean plasma fibrinogen level with other 
studies 
 
Study Mean Fibrinogen (mg /dl) 
Cristal N et al49 466 ± 89.5 
Puri et al50 447.68 ± 142.35 
Romero M et al 457 ±  46.22 
Present  study 440.61± 75.40 
 
 
High mean plasma fibrinogen (440.61 ±75.40 mg/dl) level was noted 
which is statistically significant.  This is comparable with other studies .  
 
 
 
 
 
 
 
 
 
 76 
 
Comparison of   mean   plasma   fibrinogen levels with conventional risk 
factors 
1) Smoking 
Mean plasma fibrinogen was high among smokers (433.64 mg/dl) 
compared to non smokers (421 mg/dl)  and  was  satistically significant. 
Kannel WB et al.,73  in Framingham study noted higher values of 
fibrinogen among smokers. 
 
2) Dyslipidemia 
Patients  with  dyslipidemia  had  higher  mean  plasma   fibrinogen 
(445.65 ±73.48 mg/ dl) compared to patients with normal lipid levels (428.86 
± 79.77 mg/dl). Puri  et  al.70 noted  high  fibrinogen  levels  among  patients  
with  dyslipidemia when  compared to patients  with  normal  lipids.   
 
3) Over weight and obesity 
Significantly  higher levels of fibrinogen was noted among patients 
with BMI > 30  (513.8 mg/dl )   when   compared   to   patients   with   normal 
BMI ( 438.23 mg/dl ). Difference was statistically significant. 
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Craveri et al 74  noted significantly higher plasma fibrinogen among 
patients with BMI > 30 compared to those with BMI < 25. 
 
4) Alcohol 
Significantly  high  levels  of  fibrinogen  was  noted  among  chronic  
alcoholics (443.44mg/dl) compared to occasional alcoholics (344.78 mg/dl). 
Mennen LI et al76 in DESIR study found that moderate alcohol consumption 
was associated with lower plasma fibrinogen when compared with those who 
were non drinkers or who drinks >60gm of alcohol per day. 
 
5) Hypertension and  Diabetes 
High levels of fibrinogen was noted among patients with hypertension   
but was not statistically significant. Higher levels associated with diabetic 
patients is statistically significant. 
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CONCLUSION 
•  In our study males contribute around 80% of cases.  
• All patients presented with chest pain. 
•   Dyslipidemia was   the   most   common   conventional   risk   factor   
followed   by smoking 
• Novel risk factors like fibrinogen were elevated in myocardial infarction 
patients in our study group when compared to normal levels. 
• Significant  number  of  patients in our study had hyper 
fibrinogenemia. 
• Significant  association  was  noted  between  fibrinogen  and  risk  factors  
like Dyslipidemia ,   Obesity   and    Smoking 
• Large scale randomized multicentre studies are yet to be done to understand 
the proper association between novel risk factors like fibrinogen with 
myocardial infarction. 
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SUMMARY 
In this study 70 patients with acute myocardial infarction were studied. 
 Most of the patients were males (80%). 
 Majority of the patients were between the age group of 41-60 years (64.3%). 
 All patients presented with chest pain.   Sweating   was present in 14.3% of 
patients. 
 Dyslipidemia was the most common risk factor, which was present in 60.9% 
of patients   followed by Smoking (55.7%).  Few number of patients had 
hypertension, diabetes and family history of coronary artery disease. 
 The  mean  fibrinogen  level  was  (440.61 ±  75.40 mg/dl)  which  was  high 
compared to normal fibrinogen level. 
 Smokers   had   higher   mean   fibrinogen   level compared to non smoker 
and was  statistically significant. 
 Mean fibrinogen  level was high among patients with  high LDL  and  was  
statistically significant. 
 Plasma fibrinogen was high among diabetics and was statistically 
significant. 
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 Hypertensive patients had higher fibrinogen levels when   compared  to  non  
hypertensive  patients,  but  was  not  statistically significant. 
 Patients with overweight and obesity had higher levels of mean fibrinogen 
levels and was  statistically significant. 
 Patients  who  were  chronic  alcoholics  had  higher  levels  of fibrinogen 
when compared to occasional alcoholics. 
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PROFORMA 
 
Name:  I.P.No.: Age: 
Sex:  DOA: Occupation:  DOD: 
Address:   
 
Diagnosis 
Presenting Complaints Chest pain /  Dyspnoea / Palpitation  
 
History of presenting illness 
Chest Pain 
Site - Onset- Nature - Duration: Radiation - Continuous/intermittent 
Severity - Aggravating/precipitating factors  - Relieving factors 
 
Dyspnoea 
Duration /Onset/ Time of onset in relation to pain  / NYHA Class / I/II/III/IV 
PND / orthopnoea 
 
Palpitations 
Onset / nature/ duration/ Precipitating/Aggravating factors /Relieving factors   
 Past History 
Diabetes Mellitus/ Hypertension  /  Dyslipidemia / Cerebrovascular accident 
Thyroid disorder/ Rheumatic fever/ Liver disease /Renal disease. 
 
PERSONAL HISTORY 
Diet  -  vegetarian/non-vegetarian/mixed 
Smoking  -  beedies/cigarettes 
                                                            -  duration 
                                                            -  number/day 
Alcohol  -  duration 
                                                            -  quantity……../day 
Tobacco chewing  -  Yes/No/ duration  
                                
Treatment History -   
Family History 
Coronary artery disease  -  Yes/No  
Hypertension -  Yes/No  
Diabetes  -  Yes/No  
 
 Dyslipidemia  -  Yes/No  
Sudden deaths  -  Yes/No 
 
GENERAL PHYSICAL EXAMINATION 
Condition of the patient  - Wt (in Kg)  - Ht (in length)   
- BMI (kg/m2)   
Icterus / Pallor/ Cyanosis/ Clubbing  /Pedal edema /Lymphadenopathy 
 
Vitals: 
Pulse  -  / minute 
BP  -  /mmHg in right upper limb 
Respiratory rate  -  / minute 
 Pulse 
Rate / Rhythm / Volume /Radio-radial/radio-femoral delay  
  
Other peripheral pulses: 
Blood pressure  (R) UL   (R) LL   (L) UL   (L) LL  
 
 
Systemic examination:  
1.Cardiovascular system 
a. Inspection   
Shape of the percordium  -   
 Precordial pulsation/ Other pulsation    -        
Apical impulse  - 
b.. Palpation 
Apical impulse-site  - 
Apical impulse-character / Parasternal heave / Thrill   
c.Percussion 
Cardiac borders 
d.Auscultation 
Mitral area /Tricuspid area / Aortic area / Pulmonary area    
2.Respiratory system 
Inspection /Palpation/Percussion/ Auscultation  
3. Per abdomen 
Inspection /Palpation/Percussion/ Auscultation 
 
 
 
 4. Nervous system 
Hb,  TC, DC, ESR, RBS , UREA,  
S. CREATININE 
Total Cholesterol 
 
Lipid profile- LDL/ HDL/ TGL 
 
PLASMA FIBRINOGEN- mg/ dl 
 
  
ECG: 
Rate Rhythm P wave 
QRS complex PR interval QRS complex ST 
segment 
 
-
  
 
Echocardiography 
 
 
 
 
 
 
 
 
 
LIST OF ABBREVIATIONS 
 
  
 
 
ATP Adult treatment panel 
 
BMI 
 
Body mass index 
 
CAD 
 
Coronary artery disease 
 
DBP 
 
Diastolic blood pressure 
 
ECG 
 
Electrocardiogram 
 
HDL 
 
High density lipoprotein 
 
ICAM 
 
Intracellular adhesion molecule-1 
 
IHD 
 
Ischemic heart disease 
 
JNC 
 
Joint National Committee 
 
LDL 
 
Low density lipoprotein 
 
MI 
 
Myocardial infarction 
 
MTHFR 
 
Methylene tetrahydrofolate reductase 
 
NCEP 
 
National Cholesterol Education 
Programme 
 
NO 
 
Nitric oxide 
 
PAI 
 
Plasminogen activator inhibitor 
 
PVD 
 
Peripheral vascular disease 
 
SBP 
 
Systolic blood pressure 
 
t-PA 
 
Tissue plasminogen activator 
 
USA 
 
United States of America 
 
WHO 
 
World Health Organisation 
  
PATIENT CONSENT FORM 
 
Study detail   :        “STUDY ON PLASMA FIBRINOGEN IN ACUTE MYOCARDIAL 
INFARCTION” 
Study centre :        THANJAVUR MEDICAL COLLEGE & HOSPITAL 
 
Patients Name  : 
Patients Age  : 
Identification Number: 
    
 Patient may check (     ) these boxes 
I   confirm that I have understood the purpose of procedure for the above study.  
I have the opportunity to ask question and all my questions and doubts have  
been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free  
to withdraw at any time without giving reason, without my legal rights being  
affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s  
behalf, the ethical committee and the regulatory authorities will not need  
my permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the study I agree 
to this access. However, I understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I agree not to restrict the 
use of any data or results that arise from this study. 
I agree to take part in the above study and to comply with the instructions  
given during the study and faithfully cooperate with the study team and  
to immediately inform the study staff if I suffer from any deterioration in my health or 
well being or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby  give permission to undergo complete clinical examination and  
diagnostic tests including haematological, biochemical, radiological tests. 
 
 
Signature/thumb impression:    
Patients Name and Address:                   Place   Date 
 
Signature of investigator :    
Study investigator’s Name :                         Place   Date    
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1 Murugaesan 1395932 33 M Y Y       y   Y   occ 25 144 38 220 170 130 
5
6 34 1.1 440 
IW
MI 
LV F 
N  
thrombolys
ed 
2 Pitchamuthu 1401941 25 M Y                 occ 23 102 42 133 86 72 44 30 0.9 420 
AS
MI 
LVD
EF50
% 
thrombolys
ed 
3 Palanimanikam 1408493 36 M Y Y                 21 170 60 170 
14
0 92 
5
0 24 0.9 480 
EA
W
MI 
LVD 
+MR 
not 
thrombolys
ed 
4 Ravichandran 1400506 41 M Y         Y     Y occ 22 129 145 240 
29
5 131 
5
0 28 1 294 
AS
MI 
 LV 
F N 
thrombolys
ed 
5 Suresh babu 1398653 30 M Y                   23 160 74 270 220 184 
4
2 28 1.1 464 
A
W
MI 
LV F 
N  
thrombolys
ed 
6 Chellaiyan 1409078 40 M Y         Y     y       22 168 42 148 88 86 
4
4 32 0.9 448 
AS
MI 
LVD
EF50
% 
thrombolys
ed 
7 Kaliyaperumal 1410197 42 M Y Y       Y   
    
y     25 180 64 171 
14
0 99 
4
4 52 1.2 390 
A
W
MI 
LV F 
N  
thrombolys
ed 
8 Ravichandran 1415343 48 M Y           ND     occ 23 320 64 160 85 90 
5
3 40 1.1 334 
IW
MI 
LVD
EF60
% 
not 
thrombolys
ed 
9 Selvam 1365388 36 M Y         Y   ND     30 190 52 270 130 194 
5
0 34 1 424 
IW
MI 
LV F 
N  
thrombolys
ed 
10 Venkatesan 1378431 35 M Y       Y Y       cr 22 132 70 168 180 86 
4
6 32 0.9 356 
IW
MI 
LV F 
N  
thrombolys
ed 
11 Kajamaideen 1378804 38 M Y Y Y     Y         24 156 38 175 
12
6 97 
5
3 35 0.9 416 
IW
MI 
LV F 
N  
thrombolys
ed 
12 Sulaimaan 1378707 40 M Y     Y   Y         29 146 183 220 200 133 
4
7 24 1.2 487 
EA
W
MI 
LV F 
N  
thrombolys
ed 
13 Kumar 1379043 42 M Y         Y ND   Y cr 21 258 95 260 216 179 
3
8 49 1.2 484 
IW
MI 
LVD
EF60
% 
thrombolys
ed 
14 Mohan 1382945 46 M Y                y 
    
y       25 158 70 148 
11
0 80 
4
6 40 1.3 394 
A
W
MI 
LVD
EF55
% 
not 
thrombolys
ed 
15 Lakshmanan 1377098 48 M Y         Y Y       27 250 90 154 
14
0 77 
4
9 36 0.8 440 
A
W
MI 
LV F 
N  
thrombolys
ed 
16 Kumaran 1365257 50 M Y               y   
    
y     26 150 70 152 
10
0 96 
3
6 30 1.1 280 
IL
MI 
LVD
EF50
% 
thrombolys
ed 
17 Selvaraj 1365954 64 M Y Y       Y   ND   cr 27 178 76 240 200 135 
6
5 25 1.1 455 
A
W
MI 
 LV 
F N 
not 
thrombolys
ed 
18 Mohammed ismail 1366175 58 M Y     Y   Y         24 107 60 148 88 86 
4
4 20 1 442 
A
W
MI 
LV F 
N  
thrombolys
ed 
19 Tamil selvan 1366933 51 M Y Y       Y 
    
y Y     29 130 45 160 
12
6 90 
4
5 28 0.9 480 
IW
MI 
LV F 
N  
thrombolys
ed 
20 Haseena begam 1369259 58 F Y           
     
y 
       
y      31 126 146 180 86 113 
5
0 22 1 488 
A
W
MI 
LVD
EF48
% 
not 
thrombolys
ed 
21 Puniyamoorthy 1370246 59 M Y   Y     Y 
     
y       27 182 66 171 80 110 
4
5 26 1 476 
AS
MI 
LV F 
N  
thrombolys
ed 
22 Thiyagarajan 1373215 58 M Y             
     
y   occ 23 170 80 154 
12
0 88 
4
2 25 1.2 398 
IW
MI 
LVD
EF45
% 
thrombolys
ed 
23 Panjalai 1375473 42 F Y           Y       28 152 42 196 82 124 46 42 1.1 532 
IW
MI 
LV F 
N  
thrombolys
ed 
24 Bharkath nisha 1375375 45 F Y           
      
y       32 170 64 204 
16
0 140 
3
2 38 1.1 472 
IW
MI 
LV F 
N  
thrombolys
ed 
25 Balakumar 1378253 53 M Y     Y   Y     Y   21 104 34 169 110 102 
4
5 24 1.3 338 
EA
W
MI 
LVD
EF50
% 
thrombolys
ed 
26 Pappathy 1379243 60 F Y Y                 y     .24.6 130 115 142 
22
4 57 
4
0 69 1.2 372 
AS
MI 
LV F 
N 
thrombolys
ed 
27 Jayakumar 1385235 45 M Y         Y   ND   cr 24 80 64 236 200 143 
5
3 28 1.2 486 
A
W
MI 
LV F 
N 
thrombolys
ed 
28 Andiyappasn 1387090 68 M Y         Y 
    
y       29 124 40 183 
11
6 118 
4
2 24 1.1 438 
A
W
MI 
LVD
EF50
% 
not 
thrombolys
ed 
29 Kuppusamy 1388141 57 M Y         Y        y   cr 29 130 62 188 
10
6 126 
4
1 34 1 384 
A
W
MI 
LVD
EF40
% 
thrombolys
ed 
30 Arumugam 1389034 45 M Y         Y       cr 26 156 195 215 170 125 
5
6 30 1.1 397 
IW
MI 
LV F 
N 
thrombolys
ed 
31 Manikkam 1390847 48 M Y   Y   Y Y     y     occ 30 136 130 250 
20
0 170 
4
0 38 0.9 290 
AL
MI 
LV F 
N 
thrombolys
ed 
32 Dhanam 1391771 62 F Y                  y     29 156 60 154 
12
6 87 
4
2 40 1.2 310 
IW
MI 
LVD
EF55
% 
thrombolys
ed 
33 Arumugam 1392229 60 M Y                  y   cr 28 186 70 181 
11
0 117 
4
2 26 0.8 390 
AS
MI 
LV F 
N 
thrombolys
ed 
34 Muthusamy 1392375 76 M Y         Y        y Y occ 28 137 140 190 
16
5 114 
4
3 22 1 442 
IW
MI 
LVD
EF50
% 
not 
thrombolys
ed 
35 Mohandass 1394245 48 M Y         Y         21 146 146 130 96 70 41 52 1.3 468 
A
W
MI 
LV F 
N 
thrombolys
ed 
36 Gandhi 1419752 62 M Y     Y         y 
     
y     30 180 58 173 
20
6 92 
4
0 36 0.9 510 
AL
MI 
LV F 
N 
thrombolys
ed 
37 Vishwanathan 1418674 45 M Y         Y   ND     25 215 265 180 
11
6 106 
5
0 23 1.2 426 
AL
MI 
LVD
EF45
% 
not 
thrombolys
ed 
38 Kamaraj 1420513 56 M Y       Y       y       28 105 160 166 
14
0 96 
4
2 38 1.5 370 
A
W
MI 
LV F 
N 
thrombolys
ed 
39 Iruthayamary 1419617 60  F Y Y                 23 138 88 200 
14
0 122 
5
0 36 0.8 395 
AS
MI 
LV F 
N 
thrombolys
ed 
40 Abdulkanni 1414855 68 M Y         Y     y       31 230 56 188 88 132 
3
8 28 1.1 446 
A
W
MI 
LVD
EF45
% 
not 
thrombolys
ed 
41 Balu 1395476 45 M Y         Y ND     cr 29 124 93 180 130 108 
4
6 32 1.4 460 
IW
MI 
LV F 
N 
thrombolys
ed 
42 Prabhakaran 1415127 59 M Y                   29 73 39 199 129 131 
4
2 30 0.9 394 
IL
MI 
LV F 
N 
thrombolys
ed 
43 Senthilnathan 1411150 49 M Y           
     
y     occ 28 185 153 184 
21
0 83 
5
9 22 0.8 448 
A
W
MI 
LV F 
N 
thrombolys
ed 
44 Rasu 1410483 49 M Y         Y   ND     30 172 82 184 171 109 
4
0 42 1.3 395 
AS
MI 
LVD
EF40
% 
thrombolys
ed 
45 Rajakannu 1396826 70 M Y           Y       29 210 76 169 138 100 
4
1 34 1.1 482 
IW
MI 
LVD
EF40
% 
not 
thrombolys
ed 
46 Dhanalakshmi 1397409 65 F Y                   29 95 68 138 
11
0 74 
4
2 22 0.8 280 
A
W
MI 
LV F 
N 
thrombolys
ed 
47 Habeeb rahaman 1400508 52 M Y     Y           cr 29 112 74 158 
11
0 98 
3
7 20 0.9 484 
IW
MI 
LVD
EF50
% 
thrombolys
ed 
48 Meenakshi 1400545 75 F Y     Y             27 142 110 170 96 108 43 36 1.1 410 
IW
MI 
LV F 
N 
thrombolys
ed 
49 Krishnamoorthy 1400525 52 M Y         Y 
     
y 
      
y     30 138 50 208 
15
8 138 
3
9 23 1.2 398 
IW
MI 
LV F 
N 
thrombolys
ed 
50 Sivabakiyam 1395178 61 F Y             
      
y     21 218 60 154 
15
0 80 
4
4 30 1 446 
AL
MI 
LV F 
N 
thrombolys
ed 
51 Natarajan 1395486 74 M Y Y              y 
     
y     26 130 115 241 
22
4 157 
4
0 69 1.2 465 
AS
MI 
LVD
EF45
% 
not 
thrombolys
ed 
52 Suresh 1404683 31 M Y                   24 80 64 236 200 143 
5
3 28 1.2 486 
A
W
MI 
LV F 
N 
thrombolys
ed 
53 Palaniammal 1396070 55 F Y                   21 124 40 153 
11
6 88 
4
2 24 1.1 390 
A
W
MI 
LV F 
N 
thrombolys
ed 
54 Akbar hussain 1395811 54 M Y         Y   
    
y   cr 30 130 62 188 
10
6 126 
4
1 34 1 448 
A
W
MI 
LVD
EF40
% 
thrombolys
ed 
55 Paneerselvam 1396649 45 M Y         Y       cr 27 156 195 215 
17
0 125 
5
6 30 1.1 450 
IW
MI 
LV F 
N 
not 
thrombolys
ed 
56 Selvaraj 1396797 55 M Y   Y   Y Y       occ 31 136 130 256 200 176 
4
0 38 0.9 462 
AL
MI 
LV F 
N 
thrombolys
ed 
57 Ganesan 1396701 65 M Y               y 
     
y       31 156 60 184 
12
6 117 
4
2 40 1.2 460 
IW
MI 
LV F 
N 
thrombolys
ed 
58 Natarajan 1398275 57 M Y                  y   cr 23 186 70 171 
11
0 107 
4
2 26 0.8 382 
AS
MI 
LV F 
N 
thrombolys
ed 
59 Muthayan 1398705 65 M Y         Y     Y occ 27 137 140 170 165 124 
4
3 22 1 420 
IW
MI 
LVD
EF45
% 
thrombolys
ed 
60 Pounammal 1398413 50 F Y                   24 146 146 136 96 76 41 52 1.3 376 
A
W
MI 
LV F 
N 
thrombolys
ed 
61 Kunjammal 1398491 65 F Y     Y             21 180 58 179 206 98 
4
0 36 0.9 506 
AL
MI 
LVD
EF40
% 
 not 
thrombolys
ed 
62 Ulaganathan 1398574 52 M Y         Y       y       28 215 265 181 
11
6 108 
5
0 23 1.2 344 
AL
MI 
LVD
EF45
% 
not 
thrombolys
ed 
63 Sivamani 1398910 54 M Y       Y              y     24 105 160 174 
14
0 104 
4
2 38 1.5 382 
A
W
MI 
LV F 
N 
thrombolys
ed 
64 Saroja 1406988 51 F Y Y                 30 138 88 190 140 112 
5
0 36 0.8 332 
AS
MI 
LV F 
N 
thrombolys
ed 
65 Abdulsamath 1406860 50 M Y         Y         28 230 56 137 88 82 
3
8 28 1.1 462 
A
W
MI 
LV F 
N 
thrombolys
ed 
66 Swaminathan 1405987 50 M Y         Y       cr 28 124 93 174 
13
0 102 
4
6 32 1.4 446 
IW
MI 
LV F 
N 
thrombolys
ed 
67 Indirani 1408306 60 F Y               y 
      
y     26 73 39 193 
12
9 126 
4
2 30 0.9 438 
IL
MI 
LV F 
N 
thrombolys
ed 
68 Ganapathy 1409480 47 M Y         Y       occ 23 185 153 199 210 98 
5
9 22 0.8 304 
A
W
MI 
LVD
EF45
% 
not 
thrombolys
ed 
69 Pethuraj 1404684 53 M Y   Y     Y             y     21 172 82 180 
17
1 106 
4
0 42 1.3 462 
AS
MI 
LVD
EF40
% 
thrombolys
ed 
70 Ponraman 1408570 65 M Y           Y      y     23 210 76 176 
13
8 108 
4
1 34 1.1 398 
IW
MI 
LV F 
N 
thrombolys
ed 
 
